Laura H. Porter

Clayton, VIC 3800, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Radioligand therapy in combination with CAR T cells overcomes the heterogeneous immunosuppressive prostate tumor microenvironment.

Radioligand therapy in combination with CAR T cells overcomes the heterogeneous immunosuppressive prostate tumor microenvironment.

Journal: bioRxiv : the preprint server for biology

Published: July 12, 2026

Variable cellular and radiobiological effects of [177Lu]Lu-PSMA-I&T in patient-derived models of prostate cancer.

Variable cellular and radiobiological effects of [177Lu]Lu-PSMA-I&T in patient-derived models of prostate cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: November 26, 2025

Targeting PTPN2 enhances human CAR T cell efficacy and the development of long-term memory in mouse xenograft models.

Targeting PTPN2 enhances human CAR T cell efficacy and the development of long-term memory in mouse xenograft models.

Journal: Science translational medicine

Published: October 29, 2025

Left out in the cold: Moving beyond hormonal therapy for the treatment of immunologically cold prostate cancer with CAR T cell immunotherapies.

Left out in the cold: Moving beyond hormonal therapy for the treatment of immunologically cold prostate cancer with CAR T cell immunotherapies.

Journal: The Journal of steroid biochemistry and molecular biology

Published: May 13, 2024

Defining the challenges and opportunities for using patient-derived models in prostate cancer research.

Defining the challenges and opportunities for using patient-derived models in prostate cancer research.

Journal: The Prostate

Published: December 14, 2023

How long do nosocomial pathogens persist on inanimate surfaces? A scoping review.

How long do nosocomial pathogens persist on inanimate surfaces? A scoping review.

Journal: The Journal of hospital infection

Published: December 12, 2023

Co-targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor-null prostate cancer.

Co-targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor-null prostate cancer.

Journal: The Journal of pathology

Published: October 05, 2023

The future of patient-derived xenografts in prostate cancer research.

The future of patient-derived xenografts in prostate cancer research.

Journal: Nature reviews. Urology

Published: December 09, 2022

Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models.

Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models.

Journal: Nature communications

Published: September 06, 2022

Hidden clues in prostate cancer - Lessons learned from clinical and pre-clinical approaches on diagnosis and risk stratification.

Hidden clues in prostate cancer - Lessons learned from clinical and pre-clinical approaches on diagnosis and risk stratification.

Journal: Cancer letters

Published: July 18, 2021

The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology.

The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology.

Journal: Nature communications

Published: February 15, 2021

Androgen receptor enhancer amplification in matched patient-derived xenografts of primary and castrate-resistant prostate cancer.

Androgen receptor enhancer amplification in matched patient-derived xenografts of primary and castrate-resistant prostate cancer.

Journal: The Journal of pathology

Published: December 10, 2020

Showing 1-12 of 23

Last Updated: 09/26/2026